{"protocolSection": {"identificationModule": {"nctId": "NCT00875394", "orgStudyIdInfo": {"id": "0431-189"}, "secondaryIdInfos": [{"id": "2009_571"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)", "officialTitle": "A Multicenter, Randomized, Open-label Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With T2 DM With Inadequate Glycemic Control on Metformin"}, "statusModule": {"statusVerifiedDate": "2017-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-02-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2008-06-27", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-06-27", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-04-01", "studyFirstSubmitQcDate": "2009-04-02", "studyFirstPostDateStruct": {"date": "2009-04-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-06-12", "resultsFirstSubmitQcDate": "2011-03-22", "resultsFirstPostDateStruct": {"date": "2011-04-20", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-04-28", "lastUpdatePostDateStruct": {"date": "2017-05-30", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "After 24 weeks of treatment, to assess the A1C-lowering efficacy of sitagliptin 100 mg once daily added to the regimen of patients with inadequate glycemic control on metformin monotherapy"}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Non-Insulin-Dependent"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 68, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "sitagliptin + metformin", "interventionNames": ["Drug: sitagliptin phosphate", "Drug: Comparator: metformin"]}, {"label": "2", "type": "ACTIVE_COMPARATOR", "description": "metformin + any other oral antidiabetic drug", "interventionNames": ["Drug: Comparator: metformin", "Drug: Comparator: Antidiabetic Standard of Care"]}, {"label": "3", "type": "ACTIVE_COMPARATOR", "description": "metformin", "interventionNames": ["Drug: Comparator: metformin"]}], "interventions": [{"type": "DRUG", "name": "sitagliptin phosphate", "description": "sitagliptin 100 mg Once a day (QD) for 24 weeks", "armGroupLabels": ["1"], "otherNames": ["sitagliptin"]}, {"type": "DRUG", "name": "Comparator: metformin", "description": "metformin 850 mg Twice a day (BID) for 24 weeks", "armGroupLabels": ["1", "2"], "otherNames": ["metformin"]}, {"type": "DRUG", "name": "Comparator: metformin", "description": "metformin 500 mg Three times a day (TID) to 850 mg Twice a day (BID), for 24 weeks", "armGroupLabels": ["3"], "otherNames": ["metformin"]}, {"type": "DRUG", "name": "Comparator: Antidiabetic Standard of Care", "description": "Patient can take any oral antidiabetic drug (other than metformin)", "armGroupLabels": ["2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Glycosylated Hemoglobin A1C (A1C) at Week 24", "description": "Week 24 A1C minus baseline (Week 0) A1C. The unit for A1C is \"percent\". Thus, this measure represents a difference of percent values.", "timeFrame": "Baseline and 24 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient Has Type 2 Diabetes Mellitus\n* Patient Is 30-78 Years Of Age On The Day Of Signing Informed Consent\n* Patient Is Currently On Metformin Therapy (1500 Mg/Day)\n* Patient Is A Male Or A Female Who Is Unlikely To Conceive, As Indicated By At Least One Yes Answer To The Following Questions: A) Patient Is A Male. B) Patient Is A Surgically Sterilized Female. C) Patient Is A Postmenopausal Female 45 Years Of Age With \\>2 Years Since Last Menses. D) Patient Is A Non-Sterilized Premenopausal Female And Agrees To Use An Adequate Method Of Contraception To Prevent Pregnancy Throughout The Study Starting With Visit 1 And For 14 Days After The Last Dose Of Study Medication\n* Patient Understands The Study Procedures, The Alternative Treatments Available, The Risks Involved In The Study And Voluntarily Agrees To Participate By Giving Written Informed Consent\n* Patient Has An A1c of 6.5 % - 11.0%\n\nExclusion Criteria:\n\n* Patient Has A History Of Type 1 Diabetes Mellitus Or History Of Ketoacidosis", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "30 Years", "maximumAge": "78 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf\n\nhttp://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Patients 30 to 78 years of age with inadequate glycemic control (Glycosylated hemoglobin A1C (A1C) 6.5 to 11%) on diet/exercise and metformin dosed at \u22651500 mg per day patients were to receive either sitagliptin added to ongoing metformin or \"standard care\" added to ongoing metformin.", "recruitmentDetails": "Patients were recruited in Principal Investigator's private practice, in Mexico City.\n\nFirst Patient Entered: 15 Feb 2007. Last Patient's Last Visit: 27 Jun 2008", "groups": [{"id": "FG000", "title": "Sitagliptin + Metformin", "description": "Patients administered sitagliptin and metformin"}, {"id": "FG001", "title": "Metformin + Any Non-DPP-4i Oral Antidiabetic Drug", "description": "Patients in the 'standard care' group were to receive continued treatment with metformin and usual care per practice but not to be treated with sitagliptin or another Dipeptidyl peptidase 4 inhibitor (DPP-4i). As prespecified in the protocol, no efficacy was to be assessed for patients receiving \"standard care\"."}, {"id": "FG002", "title": "Metformin Alone", "description": "Patients in the 'standard care' group were to receive continued treatment with metformin and usual care per practice but not to be treated with sitagliptin or another Dipeptidyl peptidase 4 inhibitor (DPP-4i). As prespecified in the protocol, no efficacy was to be assessed for patients receiving \"standard care\"."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "36"}, {"groupId": "FG001", "numSubjects": "23"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "36"}, {"groupId": "FG001", "numSubjects": "23"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sitagliptin + Metformin", "description": "Patients administered sitagliptin and metformin"}, {"id": "BG001", "title": "Metformin + Any Non-DPP-4i Oral Antidiabetic Drug", "description": "Patients in the 'standard care' group were to receive continued treatment with metformin and usual care per practice but not to be treated with sitagliptin or another Dipeptidyl peptidase 4 inhibitor (DPP-4i). As prespecified in the protocol, no efficacy was to be assessed for patients receiving \"standard care\"."}, {"id": "BG002", "title": "Metformin Alone", "description": "Patients in the 'standard care' group were to receive continued treatment with metformin and usual care per practice but not to be treated with sitagliptin or another Dipeptidyl peptidase 4 inhibitor (DPP-4i). As prespecified in the protocol, no efficacy was to be assessed for patients receiving \"standard care\"."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "68"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.2", "spread": "9.8"}, {"groupId": "BG001", "value": "56.0", "spread": "8.5"}, {"groupId": "BG002", "value": "53.3", "spread": "11.7"}, {"groupId": "BG003", "value": "54.69", "spread": "9.55"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "50"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "18"}]}]}]}, {"title": "Body Mass Index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "29.0", "spread": "4.5"}, {"groupId": "BG001", "value": "28.8", "spread": "5.1"}, {"groupId": "BG002", "value": "28.3", "spread": "5.2"}, {"groupId": "BG003", "value": "28.84", "spread": "4.74"}]}]}]}, {"title": "Glycosylated Hemoglobin A1C (A1C)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.8", "spread": "1.5"}, {"groupId": "BG001", "value": "8.0", "spread": "1.8"}, {"groupId": "BG002", "value": "8.2", "spread": "1.1"}, {"groupId": "BG003", "value": "8.47", "spread": "1.61"}]}]}]}, {"title": "Time since diagnosis of diabetes", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.9", "spread": "7.1"}, {"groupId": "BG001", "value": "6.8", "spread": "8.5"}, {"groupId": "BG002", "value": "10.9", "spread": "7.7"}, {"groupId": "BG003", "value": "8.43", "spread": "7.68"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Glycosylated Hemoglobin A1C (A1C) at Week 24", "description": "Week 24 A1C minus baseline (Week 0) A1C. The unit for A1C is \"percent\". Thus, this measure represents a difference of percent values.", "populationDescription": "Protocol deviations may have occurred that resulted in quality issues associated with reporting of the data.", "reportingStatus": "POSTED", "timeFrame": "Baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Sitagliptin + Metformin", "description": "Patients administered sitagliptin and metformin."}, {"id": "OG001", "title": "Metformin + Any Non-DPP-4i Oral Antidiabetic Drug", "description": "Patients in the 'standard care' group were to receive continued treatment with metformin and usual care per practice but not to be treated with sitagliptin or another Dipeptidyl peptidase 4 inhibitor (DPP-4i). As prespecified in the protocol, no efficacy was to be assessed for patients receiving \"standard care\"."}, {"id": "OG002", "title": "Metformin Alone", "description": "Patients in the 'standard care' group were to receive continued treatment with metformin and usual care per practice but not to be treated with sitagliptin or another Dipeptidyl peptidase 4 inhibitor (DPP-4i). As prespecified in the protocol, no efficacy was to be assessed for patients receiving \"standard care\"."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Sitagliptin + Metformin", "description": "Patients administered sitagliptin and metformin", "seriousNumAffected": 0, "seriousNumAtRisk": 36, "otherNumAffected": 0, "otherNumAtRisk": 36}, {"id": "EG001", "title": "Metformin + Any Non-DPP-4i Oral Antidiabetic Drug", "description": "Patients in the 'standard care' group were to receive continued treatment with metformin and usual care per practice but not to be treated with sitagliptin or another Dipeptidyl peptidase 4 inhibitor (DPP-4i). As prespecified in the protocol, no efficacy was to be assessed for patients receiving \"standard care\".", "seriousNumAffected": 0, "seriousNumAtRisk": 23, "otherNumAffected": 1, "otherNumAtRisk": 23}, {"id": "EG002", "title": "Metformin Alone", "description": "Patients in the 'standard care' group were to receive continued treatment with metformin and usual care per practice but not to be treated with sitagliptin or another Dipeptidyl peptidase 4 inhibitor (DPP-4i). As prespecified in the protocol, no efficacy was to be assessed for patients receiving \"standard care\".", "seriousNumAffected": 0, "seriousNumAtRisk": 9, "otherNumAffected": 0, "otherNumAtRisk": 9}], "otherEvents": [{"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MEDRA 13.1", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MEDRA 13.1", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "A limited number of participants were recruited into this open-label study. This study was conducted at a single site.\n\nProtocol deviations may have occurred that resulted in quality issues associated with reporting of the data."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Non-Insulin-Dependent", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}, {"id": "D000007004", "term": "Hypoglycemic Agents"}], "ancestors": [{"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "asFound": "LAMA", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}